Biovest
Encyclopedia
Biovest International, Inc is a Tampa
based biotechnology
company that is majority-owned subsidiary of Accentia Biopharmaceuticals. Their main product candidate, BiovaxID, is a cancer vaccine
that treats Follicular lymphoma
.
status with the FDA and has obtained positive Phase III clinical trial
results After a median follow-up of 4.71 years (56.6 months, range: 12.6 - 89.3 months), the median disease-free survival in the BiovaxID arm was 44.2 months compared with 30.6 months in the control arm, which is a clinically and statistically significant difference (p=0.045). The approval of Dendreon
's Provenge on April 29, 2010 indicates the FDA's willingness to accept a new class of drugs called cancer vaccine
s, of which BiovaxID is one of them. BiovaxID is also in phase II trials for mantle cell lymphoma and is being investigated in the treatment of other Non-Hodgkins Lymphomas as well.
The BiovaxID vaccine is manufactured through a process known as rescue fusion hybridization
.
Tâmpa
Tâmpa may refer to several villages in Romania:* Tâmpa, a village in Băcia Commune, Hunedoara County* Tâmpa, a village in Miercurea Nirajului, Mureş County* Tâmpa, a mountain in Braşov city...
based biotechnology
Biotechnology
Biotechnology is a field of applied biology that involves the use of living organisms and bioprocesses in engineering, technology, medicine and other fields requiring bioproducts. Biotechnology also utilizes these products for manufacturing purpose...
company that is majority-owned subsidiary of Accentia Biopharmaceuticals. Their main product candidate, BiovaxID, is a cancer vaccine
Cancer vaccine
The term cancer vaccine refers to a vaccine that either prevents infections with cancer-causing viruses, treats existing cancer or prevents the development of cancer in certain high risk individuals...
that treats Follicular lymphoma
Follicular lymphoma
Follicular lymphoma is the most common of the indolent non-Hodgkin's lymphomas, and the second most common form of non-Hodgkin's lymphomas overall. It is defined as a lymphoma of follicle center B-cells , which has at least a partially follicular pattern...
.
BiovaxID
BiovaxID obtained Orphan drugOrphan drug
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease...
status with the FDA and has obtained positive Phase III clinical trial
Clinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
results After a median follow-up of 4.71 years (56.6 months, range: 12.6 - 89.3 months), the median disease-free survival in the BiovaxID arm was 44.2 months compared with 30.6 months in the control arm, which is a clinically and statistically significant difference (p=0.045). The approval of Dendreon
Dendreon
Dendreon is a Seattle based biotechnology company. Its lead product, Provenge , is an immunotherapy for prostate cancer...
's Provenge on April 29, 2010 indicates the FDA's willingness to accept a new class of drugs called cancer vaccine
Cancer vaccine
The term cancer vaccine refers to a vaccine that either prevents infections with cancer-causing viruses, treats existing cancer or prevents the development of cancer in certain high risk individuals...
s, of which BiovaxID is one of them. BiovaxID is also in phase II trials for mantle cell lymphoma and is being investigated in the treatment of other Non-Hodgkins Lymphomas as well.
The BiovaxID vaccine is manufactured through a process known as rescue fusion hybridization
Rescue fusion hybridization
Rescue fusion hybridization is a process used to manufacture some therapeutic cancer vaccines in which individual tumor cells obtained through biopsy are fused with an antibody-secreting cell to form a heterohybridoma...
.